Anticoagulant properties of three mucopolysaccharides used in rheumatology.
Three mucopolysaccharides (MPS) used in the treatment of degenerative joint disease were compared to heparin to establish their relative potencies on 3 coagulation tests, the aPTT, the antifactor Xa activity and the dilute thrombin time. One of the compounds, Arteparon, was one fourth as potent as heparin on the aPTT, but had little or no influence on the 2 other tests. Further in vitro studies suggested that Arteparon acted at a higher level than factor Xa generation in the intrinsic amplification system and that its effect was independent of antithrombin III. In vivo administration of Arteparon confirmed its anticoagulant properties, which raises the question of the clinical use of this MPS.
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001853:Bone Marrow; D002356:Cartilage; D006025:Glycosaminoglycans / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D014020:Tissue Extracts / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D006025:Glycosaminoglycans; D014020:Tissue Extracts; C000562:Rumalon; C010034:Arteparon; D006493:Heparin